PubMed · 11664721
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Robert D Segall. 1977. Civil commitment in Alabama.. https://pubmed.ncbi.nlm.nih.gov/11664721/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
OBJECTIVES: We hypothesized that angiotensin II type-1 (AT(1)) receptor blocker (AT(1)RB) would prevent adverse left ventricular (LV) remodeling and LV dysfunction when started at the outset of mitral regurgitation (MR). BACKGROUND: Little is known regarding the efficacy of AT(1)RB treatment of MR. METHODS: Mitral regurgitation was induced by chordal disruption in adult mongrel dogs. Six normal dogs (NLs) were compared to six untreated MR dogs (MR) and seven dogs treated with the receptor blocker irbesartan (MR+AT(1)RB) started 24 h after induction of MR (60 mg/kg p.o. b.i.d.) and continued for three months. RESULTS: Treatment with AT(1)RB decreased systemic vascular resistance but did not significantly improve cardiac output, LV end-diastolic dimension (LVEDD) or LVEDD/wall thickness compared to untreated MR dogs. Resting isolated cardiomyocyte length increased in MR versus NLs and was further increased in AT(1)RB dogs. Left ventricular end-systolic dimension increased to a greater extent from baseline in AT(1)RB dogs versus untreated MR dogs (29 +/- 9% vs. 12 +/- 6%, p < 0.05), despite a significantly lower LV peak systolic pressure in AT(1)RB dogs. Plasma-angiotensin (ANG) II was elevated greater than threefold in both MR and MR+AT(1)RB versus NLs. In contrast, intracardiac ANG II was increased greater than twofold in MR dogs versus NLs, but was normalized by AT(1)RB. CONCLUSIONS: The use of AT(1)RB decreased systemic vascular resistance and attenuated local expression of the renin-angiotensin system but did not prevent adverse LV chamber and cardiomyocyte remodeling. These results suggest that blockade of the AT(1) receptor does not improve LV remodeling and function in the early myocardial adaptive phase of MR.
Explore the source record for details and available documents.
Twenty-five brands of bottled waters consisting of both purified and spring types collected randomly from three Alabama cities, USA were assessed for their suitability for human consumption. Water quality constituents analyzed include pH, conductivity, alkalinity, chloride, nitrate + nitrite, sulfate, phosphate, total carbon (TC), inorganic carbon (IC), total organic carbon (TOC), and 27 elements on the inductively coupled plasma-optical emission spectrometer (ICP-OES). The results obtained were compared with US EPA drinking water standards and the European union (EU) drinking water directive. Ni was non-detectable in all the samples and Cu, Pb, Sb, Zn, Mn, Al, Cr, Mg, P, Ca, sulfate, chloride and nitrates + nitrites were all below their respective USEPA drinking water standards or EU maximum admissible concentrations (MAC). The conductivity, pH, As, Cd, Hg, Zn, Se and Tl values in some samples exceeded the EU and USEPA standards for drinking water. No sample had pH > 8.5, but seven bottled water brands analyzed were acidic (pH < 6.5). Most of the sampled brands had TOC concentrations exceeding 3 mg/l. The concentrations of most water quality constituents analyzed, in most cases, were higher in the spring water brands compared to the purified or distilled brands of bottled water. A one-way parametric analysis of variance (ANOVA) conducted on pH, conductivity, IC, TOC, Ca, Na, K, Mg, Se, sulfate, chloride and nitrate + nitrite values for 10 brands of bottled water to ascertain the homogeneity of variances within and between the brands, suggested significant differences in variances across the brands at a 95% confidence level except for selenium, sodium and calcium.